Movement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress

Market Focus

3小时前

On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.

On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.

Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1112377946"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112377946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112377946?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112377946","market":"us","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress","media":"Market Focus","content":"<p><p>On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.</p><p>On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.</p><p>Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-04 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.</p><p>On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.</p><p>Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1112377946","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112377946","pubTimestamp":1785807528,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.On the news front, the company's associate Legend Biotech previously...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易上涨 5.15%，CARVYKTI 第二季度销售额同比飙升近 50%，加上管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}